Cargando…
Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects
BACKGROUND: The oral uptake of nanoparticles is an important route of human exposure and requires solid models for hazard assessment. While the systemic availability is generally low, ingestion may not only affect gastrointestinal tissues but also intestinal microbes. The gut microbiota contributes...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941749/ https://www.ncbi.nlm.nih.gov/pubmed/35321750 http://dx.doi.org/10.1186/s12989-022-00459-w |
_version_ | 1784673166746976256 |
---|---|
author | Landsiedel, Robert Hahn, Daniela Ossig, Rainer Ritz, Sabrina Sauer, Lydia Buesen, Roland Rehm, Sascha Wohlleben, Wendel Groeters, Sibylle Strauss, Volker Sperber, Saskia Wami, Haleluya Dobrindt, Ulrich Prior, Karola Harmsen, Dag van Ravenzwaay, Bennard Schnekenburger, Juergen |
author_facet | Landsiedel, Robert Hahn, Daniela Ossig, Rainer Ritz, Sabrina Sauer, Lydia Buesen, Roland Rehm, Sascha Wohlleben, Wendel Groeters, Sibylle Strauss, Volker Sperber, Saskia Wami, Haleluya Dobrindt, Ulrich Prior, Karola Harmsen, Dag van Ravenzwaay, Bennard Schnekenburger, Juergen |
author_sort | Landsiedel, Robert |
collection | PubMed |
description | BACKGROUND: The oral uptake of nanoparticles is an important route of human exposure and requires solid models for hazard assessment. While the systemic availability is generally low, ingestion may not only affect gastrointestinal tissues but also intestinal microbes. The gut microbiota contributes essentially to human health, whereas gut microbial dysbiosis is known to promote several intestinal and extra-intestinal diseases. Gut microbiota-derived metabolites, which are found in the blood stream, serve as key molecular mediators of host metabolism and immunity. RESULTS: Gut microbiota and the plasma metabolome were analyzed in male Wistar rats receiving either SiO(2) (1000 mg/kg body weight/day) or Ag nanoparticles (100 mg/kg body weight/day) during a 28-day oral gavage study. Comprehensive clinical, histopathological and hematological examinations showed no signs of nanoparticle-induced toxicity. In contrast, the gut microbiota was affected by both nanoparticles, with significant alterations at all analyzed taxonomical levels. Treatments with each of the nanoparticles led to an increased abundance of Prevotellaceae, a family with gut species known to be correlated with intestinal inflammation. Only in Ag nanoparticle-exposed animals, Akkermansia, a genus known for its protective impact on the intestinal barrier was depleted to hardly detectable levels. In SiO(2) nanoparticles-treated animals, several genera were significantly reduced, including probiotics such as Enterococcus. From the analysis of 231 plasma metabolites, we found 18 metabolites to be significantly altered in Ag-or SiO(2) nanoparticles-treated rats. For most of these metabolites, an association with gut microbiota has been reported previously. Strikingly, both nanoparticle-treatments led to a significant reduction of gut microbiota-derived indole-3-acetic acid in plasma. This ligand of the arylhydrocarbon receptor is critical for regulating immunity, stem cell maintenance, cellular differentiation and xenobiotic-metabolizing enzymes. CONCLUSIONS: The combined profiling of intestinal microbiome and plasma metabolome may serve as an early and sensitive indicator of gut microbiome changes induced by orally administered nanoparticles; this will help to recognize potential adverse effects of these changes to the host. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12989-022-00459-w. |
format | Online Article Text |
id | pubmed-8941749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89417492022-03-24 Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects Landsiedel, Robert Hahn, Daniela Ossig, Rainer Ritz, Sabrina Sauer, Lydia Buesen, Roland Rehm, Sascha Wohlleben, Wendel Groeters, Sibylle Strauss, Volker Sperber, Saskia Wami, Haleluya Dobrindt, Ulrich Prior, Karola Harmsen, Dag van Ravenzwaay, Bennard Schnekenburger, Juergen Part Fibre Toxicol Research BACKGROUND: The oral uptake of nanoparticles is an important route of human exposure and requires solid models for hazard assessment. While the systemic availability is generally low, ingestion may not only affect gastrointestinal tissues but also intestinal microbes. The gut microbiota contributes essentially to human health, whereas gut microbial dysbiosis is known to promote several intestinal and extra-intestinal diseases. Gut microbiota-derived metabolites, which are found in the blood stream, serve as key molecular mediators of host metabolism and immunity. RESULTS: Gut microbiota and the plasma metabolome were analyzed in male Wistar rats receiving either SiO(2) (1000 mg/kg body weight/day) or Ag nanoparticles (100 mg/kg body weight/day) during a 28-day oral gavage study. Comprehensive clinical, histopathological and hematological examinations showed no signs of nanoparticle-induced toxicity. In contrast, the gut microbiota was affected by both nanoparticles, with significant alterations at all analyzed taxonomical levels. Treatments with each of the nanoparticles led to an increased abundance of Prevotellaceae, a family with gut species known to be correlated with intestinal inflammation. Only in Ag nanoparticle-exposed animals, Akkermansia, a genus known for its protective impact on the intestinal barrier was depleted to hardly detectable levels. In SiO(2) nanoparticles-treated animals, several genera were significantly reduced, including probiotics such as Enterococcus. From the analysis of 231 plasma metabolites, we found 18 metabolites to be significantly altered in Ag-or SiO(2) nanoparticles-treated rats. For most of these metabolites, an association with gut microbiota has been reported previously. Strikingly, both nanoparticle-treatments led to a significant reduction of gut microbiota-derived indole-3-acetic acid in plasma. This ligand of the arylhydrocarbon receptor is critical for regulating immunity, stem cell maintenance, cellular differentiation and xenobiotic-metabolizing enzymes. CONCLUSIONS: The combined profiling of intestinal microbiome and plasma metabolome may serve as an early and sensitive indicator of gut microbiome changes induced by orally administered nanoparticles; this will help to recognize potential adverse effects of these changes to the host. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12989-022-00459-w. BioMed Central 2022-03-23 /pmc/articles/PMC8941749/ /pubmed/35321750 http://dx.doi.org/10.1186/s12989-022-00459-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Landsiedel, Robert Hahn, Daniela Ossig, Rainer Ritz, Sabrina Sauer, Lydia Buesen, Roland Rehm, Sascha Wohlleben, Wendel Groeters, Sibylle Strauss, Volker Sperber, Saskia Wami, Haleluya Dobrindt, Ulrich Prior, Karola Harmsen, Dag van Ravenzwaay, Bennard Schnekenburger, Juergen Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
title | Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
title_full | Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
title_fullStr | Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
title_full_unstemmed | Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
title_short | Gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
title_sort | gut microbiome and plasma metabolome changes in rats after oral gavage of nanoparticles: sensitive indicators of possible adverse health effects |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941749/ https://www.ncbi.nlm.nih.gov/pubmed/35321750 http://dx.doi.org/10.1186/s12989-022-00459-w |
work_keys_str_mv | AT landsiedelrobert gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT hahndaniela gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT ossigrainer gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT ritzsabrina gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT sauerlydia gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT buesenroland gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT rehmsascha gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT wohllebenwendel gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT groeterssibylle gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT straussvolker gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT sperbersaskia gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT wamihaleluya gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT dobrindtulrich gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT priorkarola gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT harmsendag gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT vanravenzwaaybennard gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects AT schnekenburgerjuergen gutmicrobiomeandplasmametabolomechangesinratsafteroralgavageofnanoparticlessensitiveindicatorsofpossibleadversehealtheffects |